Verici Dx plc (LON:VRCI – Get Free Report) shares dropped 0.3% during mid-day trading on Monday . The company traded as low as GBX 7.50 ($0.09) and last traded at GBX 7.73 ($0.10). Approximately 142,961 shares were traded during trading, a decline of 60% from the average daily volume of 359,174 shares. The stock had previously closed at GBX 7.75 ($0.10).
Verici Dx Price Performance
The firm has a market capitalization of £19.40 million, a PE ratio of -154.50 and a beta of 1.48. The company has a fifty day simple moving average of GBX 9.34 and a two-hundred day simple moving average of GBX 8.85. The company has a debt-to-equity ratio of 9.28, a quick ratio of 8.49 and a current ratio of 2.58.
Verici Dx Company Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Recommended Stories
- Five stocks we like better than Verici Dx
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- 3 Tickers Leading a Meme Stock Revival
- Merger or Not, Albertson’s Companies is a Good Buy
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
